160 related articles for article (PubMed ID: 36290851)
1. Rapid Review of Real-World Cost-Effectiveness Analyses of Cancer Interventions in Canada.
Guggenbickler AM; Barr HK; Hoch JS; Dewa CS
Curr Oncol; 2022 Sep; 29(10):7285-7304. PubMed ID: 36290851
[TBL] [Abstract][Full Text] [Related]
2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
3. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
4. The economic impact of the transition from branded to generic oncology drugs.
Cheung WY; Kornelsen EA; Mittmann N; Leighl NB; Cheung M; Chan KK; Bradbury PA; Ng RCH; Chen BE; Ding K; Pater JL; Tu D; Hay AE
Curr Oncol; 2019 Apr; 26(2):89-93. PubMed ID: 31043808
[TBL] [Abstract][Full Text] [Related]
5. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
6. Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs.
Saluja R; Jiao T; Koshy L; Cheung M; Chan KKW
Curr Oncol; 2021 Jan; 28(1):606-618. PubMed ID: 33498460
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
Tunis SL
Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of liraglutide in type II diabetes: a systematic review.
Zueger PM; Schultz NM; Lee TA
Pharmacoeconomics; 2014 Nov; 32(11):1079-91. PubMed ID: 25052903
[TBL] [Abstract][Full Text] [Related]
9. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
10. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
12. The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data.
Schöttler MH; Coerts FB; Postma MJ; Boersma C; Rozenbaum MH
Value Health; 2023 Jan; 26(1):91-98. PubMed ID: 35933271
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
[TBL] [Abstract][Full Text] [Related]
14. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States.
Sullivan PW; Li Q; Bilir SP; Dang J; Kavati A; Yang M; Rajput Y
Curr Med Res Opin; 2020 Jan; 36(1):23-32. PubMed ID: 31491337
[No Abstract] [Full Text] [Related]
16. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
Zou D; Lee J; Kansal A; Ma W; Harris M; Lisano J; Fenton K; Yu KS
J Med Econ; 2022; 25(1):324-333. PubMed ID: 35172685
[TBL] [Abstract][Full Text] [Related]
18. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.
Shepherd J; Jones J; Frampton GK; Tanajewski L; Turner D; Price A
Health Technol Assess; 2008 Jun; 12(28):iii-iv, ix-95. PubMed ID: 18547499
[TBL] [Abstract][Full Text] [Related]
19. The impact of cancer drug wastage on economic evaluations.
Truong J; Cheung MC; Mai H; Letargo J; Chambers A; Sabharwal M; Trudeau ME; Chan KKW
Cancer; 2017 Sep; 123(18):3583-3590. PubMed ID: 28640362
[TBL] [Abstract][Full Text] [Related]
20. Minimization of resource utilization data collected within cost-effectiveness analyses conducted alongside Canadian Cancer Trials Group phase III trials.
Cheung MC; Chan KK; Golden S; Hay A; Pater J; Prica A; Chen BE; Leighl N; Mittmann N
Clin Trials; 2021 Aug; 18(4):500-504. PubMed ID: 33866856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]